Ongoing joint soreness is worth an exam

The visit starts with when and where the joint hurts

The person examining you will ask when the soreness began and which movements worsen it. Describe swelling, stiffness, catching or giving way. Point to the exact sore area and bring the scan report. List any earlier care and how the joint responded.

Explain which task the joint now prevents. A shorter walk or lost sleep says more than a general pain rating.

QC Kinetix reviews non-surgical options with you

At QC Kinetix, regenerative treatments are done in the office without surgery and can use platelets from your blood. Platelet-rich plasma is shortened to PRP. Staff draw blood, spin out the platelets and put that portion into the sore joint using a needle. Concentrated PRP increases the platelet amount. At this clinic, medical providers check the joint and carry out treatment.

These choices may suit you when steady soreness remains after earlier care. Locked joints and hard new injuries need other care.

Locking and giving way need a different exam

Mild soreness without locking, giving way or sudden swelling may allow time for planned care. Repeated locking can mean loose or damaged tissue is blocking movement. Giving way can mean the joint isn't holding steady. Either problem may call for a surgical opinion. Broad wear may also need different care than one small damaged spot.

The visit should match care to the hands-on exam. Age or one scan can't choose the treatment alone.

Heat, fever or sudden weakness calls for prompt help

Joint heat, swelling and fever require quick medical care. After a hard injury, get help if you can't stand or take steps. Very bad pain while standing also needs quick care. The same is true for new numbness, weakness or a joint that won't straighten.

These signs require a hands-on medical check. The person examining you can test strength and blood flow.

Sources

1. In a meta-analysis of 63 studies covering 5,397 knees of 4,751 adults with NO symptoms and no injury, the pooled prevalence of cartilage defects on MRI was 24% (95% CI 15% to 34%), rising from 11% in adults under 40 to 43% in adults aged 40 and over. Meniscal tears were present in 10%, bone marrow lesions in 18% and osteophytes in 25%.

   Culvenor AG, et al. — Prevalence of knee osteoarthritis features on magnetic resonance imaging in asymptomatic uninjured adults: a systematic review and meta-analysis.. Br J Sports Med, 2019. DOI: 10.1136/bjsports-2018-099257.

2. A JBJS evidence-based review of chondral lesions of the knee sets management by lesion size, location, limb alignment and rotation, and patient demand rather than by product: osteochondral autograft transfer is described as durable and predictable for smaller lesions (under 2 cm2) in young active patients, while lesions of 2 cm2 or more are typically treated with osteochondral allograft transplantation, particulated juvenile articular cartilage, or matrix-associated chondrocyte implantation, with favourable mid- and long-term results reported for allograft or MACI in large lesions of 3 cm2 or more.

   Dekker TJ, et al. — Chondral Lesions of the Knee: An Evidence-Based Approach.. J Bone Joint Surg Am, 2021. DOI: 10.2106/JBJS.20.01161.

3. A prospective cohort of 110 patients treated with microfracture for a focal chondral defect was evaluated at a median of 12 years. Scores improved significantly from baseline and did not differ from the 5-year results, but 43 patients had needed further knee surgery including seven knee replacements, 50 had a poor long-term outcome, and normal knee function was generally not achieved. The authors called for caution in recommending microfracture.

   Solheim E, et al. — Results at 10-14 years after microfracture treatment of articular cartilage defects in the knee.. Knee Surg Sports Traumatol Arthrosc, 2016. DOI: 10.1007/s00167-014-3443-1.

4. A systematic review of 13 studies covering 821 athletes treated with microfracture in the knee found good or excellent results in 67%, return to sport in 66% at an average of eight months, return to competition at the pre-injury level in 67% of those - and declining function in 42% of athletes between two and five years after surgery.

   Mithoefer K, et al. — Clinical Outcome and Return to Competition after Microfracture in the Athlete's Knee: An Evidence-Based Systematic Review.. Cartilage, 2010. DOI: 10.1177/1947603510366576.

5. Pooling 16 of 30 studies covering 868 patients, non-operative management of osteochondral lesions of the TALUS achieved clinical success in 45% of patients (95% CI 40% to 50%) at a median 37 months, with radiographic progression of ankle osteoarthritis in 9% (95% CI 6% to 14%). Roughly half of these lesions do acceptably without an operation.

   Buck TMF, et al. — Non-operative management for osteochondral lesions of the talus: a systematic review of treatment modalities, clinical- and radiological outcomes.. Knee Surg Sports Traumatol Arthrosc, 2023. DOI: 10.1007/s00167-023-07408-w.

6. In the RESTORE randomised trial, 288 people aged 50 or over with symptomatic mild-to-moderate medial knee osteoarthritis received three weekly injections of leukocyte-poor PRP or saline placebo. At 12 months there was no significant difference in knee pain (-2.1 versus -1.8 points) and none in medial tibial cartilage VOLUME (-1.4% versus -1.2%). Twenty-nine of 31 prespecified secondary outcomes also showed no difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.